Israel joins research on psychedelics
In a significant step towards researching the therapeutic effects of psychedelics, Israel has joined the international scene through a pioneering collaboration between Optimi Health Corp. and the Institute for Psychedelic Research at Tel Aviv University (IPR-TLV). This partnership marks Optimi’s foray into the Israeli psychedelic market and promises to contribute to the advancement of knowledge in the field of mental health and addiction. In this collaboration, Optimi will supply MDMA to the IPR-TLV to support research on the effects of this compound in animal models of alcohol addiction.